Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

CAR T-cell therapy in secondary CNS lymphomas: A real-world study from the descar-t registry

Blood (2025) 146 (Supplement 1): 1012.

https://doi.org/10.1182/blood-2025-1012

Published: 2025

Journal Articles

Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry

Blood (2025) 146 (Supplement 1): 956.

https://doi.org/10.1182/blood-2025-956

Published: 2025

Journal Articles

Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for Relapsed/Refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA)

Tiy Morris, Amandine Fayard, Vivien Dupont, Elisabeth Daguenet, Catherine Thieblemont, Emmanuel Bachy, Guillaume Manson, Charles Herbaux, Ibrahim Yakoub-Agha, Thomas Gastinne, Didier Blaise, Louise Roulin, François-Xavier Gros, Pierre Bories, Roch Houot, Steven Le Gouill, Elisabeth Botelho-Nevers, Ludovic Fouillet, Jerome Cornillon

Blood (2025) 146 (Supplement 1): 1014.

https://doi.org/10.1182/blood-2025-1014

Published: 2025

Journal Articles

Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA) and indirect comparison with a synthetic control arm from the descart registry.

Blood (2025) 146 (Supplement 1): 1958.

https://doi.org/10.1182/blood-2025-1958

Published: 2025

Journal Articles

Outcomes and treatment patterns of patients with primary mediastinal b-cell lymphoma after CAR-t cell therapy failure : A descar-t analysis

Blood (2025) 146 (Supplement 1): 3733.

https://doi.org/10.1182/blood-2025-3733

Published: 2025

Journal Articles

Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE

Roch Houot, Pablo Arija, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, Cedric Portugues, Catherine Thieblemont, Markqayne Ray, Yin Yang, Sante Cundari, Camille Linot, Divyesh Mistry, Martijn Simons, Anna Gittfried, François Lemonnier

Blood (2025) 146 (Supplement 1): 3714.

https://doi.org/10.1182/blood-2025-3714

Published: 2025

Journal Articles

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Gabriel Brisou, Aurelien Belot, Emmanuel Bachy, Herve Ghesquieres, François-Xavier Gros, Krimo Bouabdallah, Guillaume Cartron, Roberta Di Blasi, Roch Houot, Cedric Rossi, Amandine Durand, Fabien Le Bras, Corinne Haioun, Thomas Gastinne, Remy Dulery, Pierre Bories, Fabrice Jardin, Blandine Guffroy, Luc-Matthieu Fornecker, Cristina Castilla-Llorente, Gandhi Damaj, Franck Morschhauser, Michael Loschi, Stephanie Guidez, Choquet Sylvain, Aline Schmidt, Laurianne Drieu La Rochelle, Marie-Thérèse Rubio, Sylvain Carras, Jacques-Olivier Bay, Adrien Chauchet, Magalie Joris, Ludovic Fouillet, Laure Lebras, Julie Abraham, Fontanet Bijou, Olivier Hermine, Antoine Bonnet, Justine Decroocq, Sandy Amorim, Nadine Morineau, Pauline Lionne, Sophie Dennetiere, Laura Herbreteau, Bernard Drenou, Launay Vincent, Gaelle Olivier, Gaëlle Labouré, Olivier Fitoussi, Christophe Fruchart, Cecile Leyronnas, Fanny Cherblanc, Elodie Gat, Benoit Tessoulin

Blood (2025) 146 (Supplement 1): 2764.

https://doi.org/10.1182/blood-2025-2764

Published: 2025

Journal Articles

Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry

Blood (2025) 146 (Supplement 1): 2745.

https://doi.org/10.1182/blood-2025-2745

Published: 2025

Journal Articles

Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry

Blood (2025) 146 (Supplement 1): 127.

https://doi.org/10.1182/blood-2025-127

Published: 2025

Journal Articles

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: a DESCAR-T Registry and International Collaborative Study

Blood (2025) 146 (Supplement 1): 5490.

https://doi.org/10.1182/blood-2025-5490

Published: 2025

Journal Articles

Glofitamab for patients with Non–Large B-cell lymphoma refractory or relapsing after anti-CD19 CAR T-cell therapy: Final bicar study (LYSA) results.

Blood (2025) 146 (Supplement 1): 5923.

https://doi.org/10.1182/blood-2025-5923

Published: 2025

Journal Articles

Real-world data of lisocabtagene maraleucel as second line therapy for patients with large B-cell lymphoma: Updated Results of the french descar-T registry by lysa

Gabriel Brisou, Roch Houot, Roberta Di Blasi, Guillaume Cartron, Franck Morschhauser, Emmanuel Bachy, Cristina Castilla-Llorente, Axel André, Michael Loschi, François-Xavier Gros, Pierre Bories, Blandine Guffroy, Eve Gehlkopf, Elodie Gat, Benoit Tessoulin

Blood (2025) 146 (Supplement 1): 4541.

https://doi.org/10.1182/blood-2025-4541

Published: 2025

Journal Articles

Carmod, an Open-Label, Multicenter, Proof of Concept, Phase II Trial, Investigating the Safety and Efficacy of Golcadomide in Post-CART for Patients with Relapsed/Refractory High-Risk Aggressive Large B-Cell Lymphoma

Catherine Thieblemont, François-Xavier Gros, Sandrine Roulland, Salim Kanoun, Veronique Meignin, Celine Row, Thierry Lamy, Emmanuel Gomez, Karin Tarte, Gabriel Brisou

Blood (2024) 144 (Supplement 1): 7226.

https://doi.org/10.1182/blood-2024-207843

Published: 2024

Journal Articles

Hemophagocytic Lymphohistiocytosis-like Syndrome after Anti-CD19 CAR T-Cells for B-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia: A Lysa, Sfce and Graall Study from the Descar-T Registry

Blood (2024) 144 (Supplement 1): 528.

https://doi.org/10.1182/blood-2024-208304

Published: 2024

Journal Articles

Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK-Positive Anaplastic Large-Cell Lymphoma: A Study from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Blood (2024) 144 (Supplement 1): 4946.

https://doi.org/10.1182/blood-2024-212055

Published: 2024

Journal Articles

Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Blood (2024) 144 (Supplement 1): 4505.

https://doi.org/10.1182/blood-2024-200614

Published: 2024

Journal Articles

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

Blood (2024) 143 (26): 2804–2807.

https://doi.org/10.1182/blood.2024024452

Published: 2024

Includes: Supplemental data

Journal Articles

Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study

Blood (2023) 142 (Supplement 1): 893.

https://doi.org/10.1182/blood-2023-177703

Published: 2023

Journal Articles

Outcomes of High-Grade B-Cell Lymphoma As Compared to Other Large B-Cell Lymphoma Subtypes in Patients Treated with CD19-Directed CAR-T Cells at 3 rd Line or More. a Lysa Study Based on the French Descart-Registry.

Xavier Phina-Ziebin, Emmanuel Bachy, Francois Xavier Gros, Roberta Di Blasi, Charles Herbaux, Jacques-Olivier Bay, Sylvain Carras, Pierre Bories, René-Olivier Casasnovas, Fabrice Jardin, Franck Morschhauser, Blandine Guffroy, Elodie Gat, Julien Calvani, Marie Parrens, Elsa Poullot, Alexandra Traverse-Glehen, Louise Roulin

Blood (2023) 142 (Supplement 1): 3112.

https://doi.org/10.1182/blood-2023-180707

Published: 2023

Journal Articles

Verlen, “Very Elderly Rituximab Associated to Lenalidomide - Tafasitamab Combination in Frontline DLBCL Patients”, a Phase II Open-Label Study Evaluating Efficacy of Lenalinomide and Tafasitamab Combination Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older from the Lysa Group

Benoit Tessoulin, Julien Depaus, Pierre Feugier, Ludovic Fouillet, Julie Abraham, Sandy Amorin, Fabrice Jardin, Franck Morschhauser, Catherine Thieblemont, François-Xavier Gros, Bertrand Joly, Hacene Zerazhi, Sophie Bernard, Adrien Chauchet, Stéphane Vigouroux, Christophe Bonnet, Sarah Bailly, Steven Le Gouill

Blood (2023) 142 (Supplement 1): 3094.

https://doi.org/10.1182/blood-2023-173265

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CAR T-cell therapy in secondary CNS lymphomas: A real-world study from the descar-t registry

Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry

Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for Relapsed/Refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA)

Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA) and indirect comparison with a synthetic control arm from the descart registry.

Outcomes and treatment patterns of patients with primary mediastinal b-cell lymphoma after CAR-t cell therapy failure : A descar-t analysis

Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry

Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: a DESCAR-T Registry and International Collaborative Study

Glofitamab for patients with Non–Large B-cell lymphoma refractory or relapsing after anti-CD19 CAR T-cell therapy: Final bicar study (LYSA) results.

Real-world data of lisocabtagene maraleucel as second line therapy for patients with large B-cell lymphoma: Updated Results of the french descar-T registry by lysa

Carmod, an Open-Label, Multicenter, Proof of Concept, Phase II Trial, Investigating the Safety and Efficacy of Golcadomide in Post-CART for Patients with Relapsed/Refractory High-Risk Aggressive Large B-Cell Lymphoma

Hemophagocytic Lymphohistiocytosis-like Syndrome after Anti-CD19 CAR T-Cells for B-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia: A Lysa, Sfce and Graall Study from the Descar-T Registry

Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK-Positive Anaplastic Large-Cell Lymphoma: A Study from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study

Outcomes of High-Grade B-Cell Lymphoma As Compared to Other Large B-Cell Lymphoma Subtypes in Patients Treated with CD19-Directed CAR-T Cells at 3 rd Line or More. a Lysa Study Based on the French Descart-Registry.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only